Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
Disease site
Ovary
Pubmed link
Publication month/year
Jan 2018
Study question
To investigate whether the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery would improve outcomes among patients who were receiving neoadjuvant chemotherapy for stage III epithelial cancer.
Type of study
Multicenter, open-label, phase 3, randomized clinical trial (RCT)
Interventions compared
Interval cytoreductive surgery vs Interval cytoreductive surgery with HIPEC
Experimental arm (Intervention)
Interval cytoreductive surgery with HIPEC with cisplatin (100mg per square meter)
Control arm
Interval cytoreductive surgery
Primary outcome
Recurrence-free survival
Secondary outcome
- Overall survival
- Side-effect profile
Inclusion criteria
- Newly diagnosed stage III epithelial ovarian, fallopian tube, or peritoneal cancer who were referred for neoadjuvant chemotherapy
- WHO performance status score of 0 to 2
- Normal blood counts
- Adequate renal function
Exclusion criteria
Cases that did not meet the inclusion criteria were excluded
Results
| Intervention arm (Surgery-Plus-HIPEC group) | Control arm (Surgery group) | |
|---|---|---|
| Randomised (n) | 122 | 123 |
| Received treatment(n) | 118 | 122 |
| Recurrence-free survival | 14.2 months | 10.7 months |
| Overall survival | 45.7 months | 33.9 months |
| Adverse events of grade 3or4 | 27% | 25% |
Conclusions
The addition of Hyperthermic Intraperitoneal Chemotherapy to interval cytoreductive surgery resulted in longer recurrence-free survival and overall survival, and did not result in higher rates of side effects.